A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization TACE in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma EMERALD-1

Brief Summary

Type:
Liver

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03778957

Study #:
STUDY00145335

Start Date:
Dec 03, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03778957

View Complete Trial Details & Eligibility at ClinicalTrials.gov